Stock Analysis

3 KRX Growth Companies With High Insider Ownership And Up To 99% Earnings Growth

KOSE:A352820
Source: Shutterstock

Over the last 7 days, the South Korean market has experienced a 1.4% decline, while remaining flat overall in the past year. In this context of anticipated 30% annual earnings growth, companies with high insider ownership and significant earnings potential can be particularly appealing for investors seeking promising opportunities.

Top 10 Growth Companies With High Insider Ownership In South Korea

NameInsider OwnershipEarnings Growth
People & Technology (KOSDAQ:A137400)16.4%35.6%
Seojin SystemLtd (KOSDAQ:A178320)30.5%52.1%
Bioneer (KOSDAQ:A064550)15.8%97.6%
ALTEOGEN (KOSDAQ:A196170)26.6%99.5%
Oscotec (KOSDAQ:A039200)26.1%122%
Vuno (KOSDAQ:A338220)19.5%110.9%
HANA Micron (KOSDAQ:A067310)18.3%100.3%
UTI (KOSDAQ:A179900)33.1%134.6%
Techwing (KOSDAQ:A089030)18.7%83.6%
INTEKPLUS (KOSDAQ:A064290)16.3%96.7%

Click here to see the full list of 86 stocks from our Fast Growing KRX Companies With High Insider Ownership screener.

Below we spotlight a couple of our favorites from our exclusive screener.

Seojin SystemLtd (KOSDAQ:A178320)

Simply Wall St Growth Rating: ★★★★★★

Overview: Seojin System Co., Ltd. operates in the telecom equipment industry, offering products such as repeaters, mechanical products, and LED equipment, with a market cap of ₩1.60 billion.

Operations: The company's revenue segments include the EMS Division generating ₩1.52 billion and the Semiconductor segment contributing ₩169.98 million.

Insider Ownership: 30.5%

Earnings Growth Forecast: 52.1% p.a.

Seojin System Ltd. demonstrates substantial growth potential with earnings forecasted to grow significantly at 52.05% annually, outpacing the broader Korean market's expected growth. Despite a volatile share price and recent shareholder dilution, the company trades well below its estimated fair value. Recent private placements totaling ₩100 billion signal strategic financial maneuvers aimed at strengthening capital structure, although interest payments remain inadequately covered by earnings. The lack of insider trading activity suggests stable insider confidence in future prospects.

KOSDAQ:A178320 Ownership Breakdown as at Oct 2024
KOSDAQ:A178320 Ownership Breakdown as at Oct 2024

ALTEOGEN (KOSDAQ:A196170)

Simply Wall St Growth Rating: ★★★★★★

Overview: ALTEOGEN Inc. is a biotechnology company that develops long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars, with a market cap of ₩17.85 trillion.

Operations: The company's revenue is primarily derived from its biotechnology segment, amounting to ₩90.79 billion.

Insider Ownership: 26.6%

Earnings Growth Forecast: 99.5% p.a.

ALTEOGEN Inc. is poised for significant growth, with revenue expected to rise 64.2% annually, surpassing the Korean market's average. The recent MFDS approval of Tergase® marks a pivotal transition to commercialization, leveraging its high purity and low immunogenicity advantages. Despite past shareholder dilution and share price volatility, the company trades significantly below estimated fair value. Profitability is projected within three years, reflecting above-average market growth expectations without substantial insider trading activity recently noted.

KOSDAQ:A196170 Ownership Breakdown as at Oct 2024
KOSDAQ:A196170 Ownership Breakdown as at Oct 2024

HYBE (KOSE:A352820)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: HYBE Co., Ltd. operates in music production, publishing, and artist development and management, with a market cap of ₩7.09 trillion.

Operations: The company's revenue is primarily derived from three segments: Label (₩1.28 trillion), Platform (₩361.12 billion), and Solution (₩1.24 trillion).

Insider Ownership: 32.5%

Earnings Growth Forecast: 42.2% p.a.

HYBE demonstrates strong growth potential, with earnings forecasted to grow significantly at 42.2% annually, outpacing the Korean market. Despite recent fluctuations in net income and earnings per share due to large one-off items, the company trades below its estimated fair value by 27.4%. The recent completion of a share buyback program for KRW 26.09 billion aims to stabilize stock prices. Analysts anticipate a substantial price increase, though insider trading activity remains minimal recently.

KOSE:A352820 Earnings and Revenue Growth as at Oct 2024
KOSE:A352820 Earnings and Revenue Growth as at Oct 2024

Key Takeaways

Want To Explore Some Alternatives?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Valuation is complex, but we're here to simplify it.

Discover if HYBE might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com